Related Experiment Video
Updated: May 29, 2026

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
Published on: August 14, 2018
Development of indole compounds as small molecule fusion inhibitors targeting HIV-1 glycoprotein-41
Guangyan Zhou1, Dong Wu, Beth Snyder
1Department of Basic Sciences, Touro University-California, 1310 Club Drive, Mare Island, Vallejo, California 94592, United States. guangyan.zhou@tu.edu
Abstract:
Nonpeptide inhibition of fusion remains an important goal in anti-HIV research, due to its potential for low cost prophylaxis or prevention of cell-cell transmission of the virus. We report here on a series of indole compounds that have been identified as fusion inhibitors of gp41 through a structure-based drug design approach. Experimental binding affinities of the compounds for the hydrophobic pocket were strongly correlated to fusion inhibitory data (R(2) = 0.91), and corresponding inhibition of viral replication confirmed the hydrophobic pocket as a valid target for low molecular weight fusion inhibitors. The most active compound bound to the hydrophobic pocket and inhibited cell-cell fusion and viral replication at submicromolar levels. A common binding mode for the inhibitors in this series was established by carrying out docking studies using structures of gp41 in the Protein Data Bank. The molecules were flexible enough to conform to the contours of the pocket, and the most active compound was able to adopt a structure mimicking the hydrophobic contacts of the D-peptide PIE7. The results enhance our understanding of indole compounds as inhibitors of gp41.
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Antiviral Nucleoside Inhibitors

